PBYI
NASDAQ · Biotechnology
Puma Biotechnology Inc
$7.56
+0.33 (+4.56%)
Open$7.36
Previous Close$7.23
Day High$7.59
Day Low$7.26
52W High$7.90
52W Low$3.03
Volume—
Avg Volume211.4K
Market Cap384.80M
P/E Ratio15.78
EPS$0.48
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-27.9% upside
Current
$7.56
$7.56
Target
$5.45
$5.45
$2.99
$5.45 avg
$6.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 236.68M | 236.56M | 42.11M |
| Net Income | 32.24M | 29.00M | 7.89M |
| Profit Margin | 13.6% | 12.9% | 18.7% |
| EBITDA | 49.99M | 47.47M | 13.15M |
| Free Cash Flow | — | — | 4.76M |
| Rev Growth | +0.1% | +0.1% | +7.6% |
| Debt/Equity | 0.17 | 0.17 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |